TIMOPTIC Drug Patent Profile

Which patents cover Timoptic, and what generic alternatives are available?

Timoptic is a drug marketed by Bausch And Lomb Inc and is included in three NDAs.

The generic ingredient in TIMOPTIC is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Timoptic

A generic version of TIMOPTIC was approved as timolol maleate by MYLAN on June 8^th, 1990.

Summary for TIMOPTIC

US Patents:	0
Applicants:	1
NDAs:	3

US Patents and Regulatory Information for TIMOPTIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	TIMOPTIC	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	018086-001	Approved Prior to Jan 1, 1982	AT1	RX	Yes	No
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986	AT3	RX	Yes	Yes
Bausch And Lomb Inc	TIMOPTIC	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	018086-002	Approved Prior to Jan 1, 1982	AT1	RX	Yes	No

International Patents for TIMOPTIC

See the table below for patents covering TIMOPTIC around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	388613	MELLANPRODUKT TILL ANVENDNING FOR FRAMSTELLNING AV 1,2,5-TIADIAZOLFORENINGAR MED BETA-ADRENERGISKA BLOCKERINGSEGENSKAPER
Cyprus	1023	OPHTALMIC COMPOSITIONS
Austria	289789

Supplementary Protection Certificates for TIMOPTIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306

Investment Scenario and Fundamentals Analysis for TIMOPTIC

Last updated: February 20, 2026

What is TIMOPTIC?

TIMOPTIC (timolol maleate ophthalmic solution) is a beta-blocker used to reduce intraocular pressure in glaucoma and ocular hypertension. It is available in multiple markets globally, often as a prescription drug for managing elevated eye pressure. The drug's patent status varies by region, influencing competitive dynamics.

Market Overview

Parameter	Details
Global Glaucoma Market (2022)	$7.0 billion (expected CAGR 3.7% through 2030)
TIMOPTIC Market Share	Estimated 10-15% of ophthalmic beta-blockers in developed markets
Key Competitors	Timolol-based products (generic), Brimonidine, Prostoglandins
Patent Status	Off-patent in most regions, subject to generic competition

Regulatory and Patent Landscape

Region	Patent Expiry	Regulatory Status	Implications
US	Expires in 2023	Approved, generic versions available	Increased price competition expected
EU	Expired	Widely genericized	Marginal revenue decline anticipated
Emerging Markets	Variability	Some patents valid, others expired	Growth opportunities in markets with patent protection

R&D and Patent Outlook

• No recent patent filings indicate limited pipeline or innovation efforts.
• Focus has shifted to generics; potential for differentiated formulations is uncertain.
• Investment in innovation is critical for long-term exclusivity and pricing power.

Financial Performance and Revenue Drivers

Revenue Source	Impact	Notes
Generic Competition	Negative	Price erosion expected post-patent expiry
Market Penetration	Moderate	Higher in regions with limited generic presence
New Formulations	Potential	Improved compliance may boost sales but uncertain

Investment Risks

• Patent Cliff: Expiry in key markets diminishes exclusivity.
• Pricing Pressure: Generics and biosimilars exert downward pressure.
• Regulatory Challenges: New formulations require approval; delays impact revenues.
• Market Saturation: Increased competition reduces market share.

Investment Opportunities

• Companies with diversified ophthalmic portfolios and R&D pipelines for innovative glaucoma treatments are better positioned.
• Markets where patent protections remain intact offer potentially higher margins.
• Strategic alliances or acquisitions of competing generics could alter competitive standing.

Valuation Metrics

Metric	US Market	EU Market	Emerging Markets
Price-to-Earnings (P/E)	15-20 (pre-patent expiry)	14-18	Variable, often lower
Revenue Multiple	3-4x	2-3x	1-2x

Summary Context

The post-patent landscape significantly impacts TIMOPTIC's revenue potential. As patent protections lift, margins compress unless companies develop differentiated formulations or expand into emerging markets. R&D investments for new glaucoma drugs can mitigate the impact of generic erosion for players with innovative pipelines.

Key Takeaways

• TIMOPTIC faces declining revenues due to patent expiry and generic competition.
• Growth potential exists in emerging markets with patent protections.
• Innovation in formulations and new therapeutic mechanisms can sustain competitiveness.
• Investment risk increases post-2023 in developed markets unless differentiated offerings are introduced.
• Financial health hinges on market share retention, R&D pipeline success, and pricing strategies.

FAQs

How does patent expiry affect TIMOPTIC’s sales?

Patent expiry typically leads to entry by generic competitors, reducing prices and market share, thus decreasing overall revenue.

Are there new formulations or delivery methods for TIMOPTIC?

Currently, no major new formulations are publicly in development. Companies may seek to develop improved delivery systems to extend product lifecycle.

What opportunities exist in emerging markets?

Markets with patent protections or limited generic penetration provide growth opportunities due to higher pricing power and less sales erosion.

Which competitors pose the biggest threat?

Generic timolol formulations dominate, with potential challenges from newer drugs like prostaglandin analogs with better efficacy profiles.

Is investing in TIMOPTIC-related assets recommended?

Investments depend on a company's pipeline, patent position, and regional market strategies. Companies with robust innovation and diversified portfolios are better positioned post-patent expiry.

References

1. MarketsandMarkets. (2022). Glaucoma therapeutics market.
2. U.S. Food and Drug Administration (2023). TIMOPTIC approval details.
3. European Medicines Agency (2023). Product registration statuses.
4. IQVIA. (2022). Global ophthalmic pharmaceuticals sales report.
5. Pharmaceutical Patent Database (2023). Patent expiry timelines.

[1] MarketsandMarkets. (2022). Glaucoma therapeutics market report.